Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7827323 | 0.79 | ECE1 (0.39) | LMNAKDM4ECA1CA2 | |
| SCHEMBL2988199 | 0.77 | TDP1 (0.36) | EGLN1APEX1TDP1KMT2APOLB | |
| SCHEMBL9889353 | 0.73 | MMP2 (0.44) | ALDH1A1 | |
| SCHEMBL21461381 | 0.72 | — | — | |
| Guanidino Acetate SCHEMBL28788166 | 0.71 | MAPT (0.38) | EGLN1APEX1TDP1KMT2APOLB | |
| Guanidino Acetate SCHEMBL2428942 | 0.71 | MAPT (0.38) | EGLN1APEX1TDP1KMT2APOLB | |
| SCHEMBL5538105 | 0.70 | — | — | |
| SCHEMBL1551259 | 0.70 | — | — | |
| SCHEMBL2984431 | 0.69 | TDP1 (0.33) | EGLN1APEX1TDP1KMT2APOLB | |
| SCHEMBL11130677 | 0.69 | EGLN1 (0.46) | EGLN1APEX1TDP1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100179106-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | GENCIA CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090298943-A1 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | AVICENA GROUP, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-7285573-B2 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| WO-2007096164-A2 | CREATINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIAS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-08-30 | — | — | WO | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | EGLN1 3171/4885APEX1 4664/4885TDP1 1558/4885 |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | EGLN1 3171/4885APEX1 4664/4885TDP1 1558/4885 |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | CKMT1A; CKMT1B, PC, PCK2 | EGLN1 4790/4885APEX1 2698/4885TDP1 273/4885 |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | EGLN1 3052/4885APEX1 488/4885TDP1 151/4885 |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | EGLN1 3052/4885APEX1 488/4885TDP1 151/4885 |
| US-20090298943-A1 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | CKMT1A; CKMT1B, PCK1, TKT | EGLN1 4439/4885APEX1 4619/4885TDP1 1371/4885 |
| US-20100179106-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | PC, CKMT1A; CKMT1B, SLC25A1 | EGLN1 3374/4885APEX1 1366/4885TDP1 1273/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | EGLN1 3171/4885APEX1 4664/4885TDP1 1558/4885 |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | CKMT1A; CKMT1B, PC, PCK2 | EGLN1 4790/4885APEX1 2698/4885TDP1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.